3 QUESTIONS ON . . . The Impact of Historical Redlining on… : Oncology Times
An abstract is unavailable.
Related Articles
Current Issue : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
Welcome! You are invited to join a webinar: Skin VJSessions: Therapeutic Advances in PD-1 Refractory Skin Cancer. After registering, you will receive a confirmation email about joining the webinar.
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
Watch Free Movies & TV Shows Online | wedotv
Stream a wide selection of movies and TV shows for free on wedotv. No subscription needed – just hit play and enjoy unlimited entertainment!
JZP458 in ALL/LBL: Complete follow-up results from AALL1931 trial
We summarize the results of the complete analysis from the AALL1931 trial assessing the efficacy and safety of JZP458 in children and adult patients with…
Validation of updated ELN 2022 risk stratification in adult patients with AML
Ruhnke et al. published a retrospective cohort study in Blood Advances validating the prognostic value of the 2022 ELN classification in patients with newly diagnosed…
De-escalating treatment in patients with breast cancer post-surgery
Icro Meattini, MD, University of Florence, Florence, Italy, comments on the current treatment strategies for patients after breast cancer surgery, highlighting the optimization of de-escalation…
Results of a Phase II trial investigating loncastuximab tesirine + rituximab in high-risk R/R FL
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, presents the results of a Phase II investigator-initiated study (NCT04998669) investigating a combination of loncastuximab tesirine…
Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
